Dnaprint Genomics Stock Analysis
DNAPrint Genomics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of DNAPrint Genomics stock analysis is to determine its intrinsic value, which is an estimate of what DNAPrint Genomics is worth, separate from its market price. There are two main types of DNAPrint Genomics' stock analysis: fundamental analysis and technical analysis.
The DNAPrint Genomics stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and DNAPrint Genomics' ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DNAPrint Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. DNAPrint Stock Analysis Notes
The company had not issued any dividends in recent years. DNAPrint Genomics had 1:20 split on the 12th of July 2005. DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany. DNAPRINT GENOMICS is traded on OTC Exchange in the United States. To learn more about DNAPrint Genomics call the company at 941-366-3400.DNAPrint Genomics Quarterly Total Revenue |
|
DNAPrint Genomics Investment Alerts
| DNAPrint Genomics generated a negative expected return over the last 90 days | |
| DNAPrint Genomics has some characteristics of a very speculative penny stock | |
| DNAPrint Genomics has a very high chance of going through financial distress in the upcoming years | |
| DNAPrint Genomics currently holds 240 K in liabilities. DNAPrint Genomics has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about DNAPrint Genomics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.43 M. Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 446.37 K. | |
| DNAPrint Genomics currently holds about 134.35 K in cash with (5.78 M) of positive cash flow from operations. | |
| DNAPrint Genomics has a frail financial position based on the latest SEC disclosures |
DNAPrint Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 386.76 K.DNAPrint Profitablity
The company has Profit Margin (PM) of (2.36) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.31.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.11) | (1.16) | |
| Return On Capital Employed | 2.28 | 2.13 | |
| Return On Assets | (1.08) | (1.14) | |
| Return On Equity | 3.83 | 4.02 |
Management Efficiency
DNAPrint Genomics has return on total asset (ROA) of (1.05) % which means that it has lost $1.05 on every $100 spent on assets. This is way below average. DNAPrint Genomics' management efficiency ratios could be used to measure how well DNAPrint Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The DNAPrint Genomics' current Return On Equity is estimated to increase to 4.02, while Return On Tangible Assets are projected to decrease to (1.16). At this time, DNAPrint Genomics' Other Current Assets are most likely to increase significantly in the upcoming years. The DNAPrint Genomics' current Total Current Assets is estimated to increase to about 10.6 M, while Return On Tangible Assets are projected to decrease to (1.16).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.01) | (0.01) | |
| Tangible Book Value Per Share | (0.01) | (0.01) | |
| Enterprise Value Over EBITDA | (1.01) | (1.06) | |
| Price Book Value Ratio | (1.03) | (0.98) | |
| Enterprise Value Multiple | (1.01) | (1.06) | |
| Price Fair Value | (1.03) | (0.98) | |
| Enterprise Value | 11.5 M | 14.8 M |
Evaluating the management effectiveness of DNAPrint Genomics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The DNAPrint Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
DNAPrint Genomics technical analysis allows you to utilize past data patterns in order to determine a pattern that computes the direction of the firm's future prices.DNAPrint Genomics Price Movement Analysis
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of DNAPrint Genomics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out DNAPrint Genomics short-term fluctuations and highlight longer-term trends or cycles.
DNAPrint Genomics Outstanding Bonds
DNAPrint Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DNAPrint Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DNAPrint bonds can be classified according to their maturity, which is the date when DNAPrint Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| DPL 435 percent Corp BondUS233293AQ29 | View | |
| DNBNO 1127 16 SEP 26 Corp BondUS23329PAF71 | View | |
| DNBNO 1535 25 MAY 27 Corp BondUS23329PAG54 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
About DNAPrint Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how DNAPrint Genomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DNAPrint shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as DNAPrint Genomics. By using and applying DNAPrint Stock analysis, traders can create a robust methodology for identifying DNAPrint entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (4.19) | (3.98) | |
| Net Loss | (4.57) | (4.80) | |
| Gross Profit Margin | 0.36 | 0.46 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding DNAPrint Genomics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Complementary Tools for DNAPrint Stock analysis
When running DNAPrint Genomics' price analysis, check to measure DNAPrint Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNAPrint Genomics is operating at the current time. Most of DNAPrint Genomics' value examination focuses on studying past and present price action to predict the probability of DNAPrint Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNAPrint Genomics' price. Additionally, you may evaluate how the addition of DNAPrint Genomics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |